within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BC01_Nebacumab;

model Nebacumab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 5.555555555555556e-08,
    adminDuration = 600,
    adminMass = 700 / 1000000,
    adminCount = 1,
    Vd = 0.0035,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.002,
    k12 = 4.166666666666666e-08,
    k21 = 4.166666666666666e-08);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Nebacumab</td></tr><tr><td>ATC code:</td><td>J06BC01</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>700</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Nebacumab (Centoxin) is a human monoclonal antibody that was developed for treatment of sepsis caused by gram-negative bacteria, specifically targeting endotoxin. The drug was withdrawn from development due to lack of efficacy and is not approved for clinical use today.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies in humans available. Parameter estimates are extrapolated based on typical IgG1 monoclonal antibody behavior in adults following intravenous dosing.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J06BC01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Nebacumab;
